Fred Aslan Sells 27,116 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 27,116 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $244,315.16. Following the sale, the chief executive officer owned 1,535,082 shares in the company, valued at $13,831,088.82. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $7.84 on Thursday. The firm has a market capitalization of $193.80 million, a P/E ratio of -2.21 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a one year low of $1.47 and a one year high of $14.53. The company’s fifty day moving average is $8.36 and its two-hundred day moving average is $5.67.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, sell-side analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC raised its stake in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares during the last quarter. Renaissance Technologies LLC raised its stake in Artiva Biotherapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after purchasing an additional 37,053 shares during the last quarter. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics in the 4th quarter valued at about $341,000. Finally, Jane Street Group LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at about $67,000.

Analyst Ratings Changes

ARTV has been the topic of several research analyst reports. Cantor Fitzgerald boosted their target price on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Needham & Company LLC lifted their price target on Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Wedbush lifted their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Finally, Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Trending Headlines about Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva announced multiple AlloNK® data presentations for the upcoming EULAR 2026 Congress, including a late-breaking oral presentation highlighting clinical efficacy comparable to autologous CAR T-cell therapy in rheumatologic diseases. Article Title
• Positive Sentiment: The company appointed veteran biotech executive Diego Miralles, M.D., as President and Head of Research and Development, which could strengthen leadership and development execution. Article Title
• Neutral Sentiment: Artiva disclosed several insider sales by CEO Fred Aslan, COO Jennifer Bush, SVP Heather Raymon, and insider Christopher Horan/ Subhashis Banerjee at $9.01 per share; the company said these were primarily for tax withholding related to equity vesting, which makes them less alarming than open-market selling. Article Title
• Neutral Sentiment: Recent analyst commentary remains constructive overall, with multiple firms raising price targets sharply, but the stock also faces skepticism from some ratings changes and a still-loss-making earnings profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.95 per share, wider than expectations, reinforcing concerns about ongoing losses and execution risk.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.